Cytotoxic benzodiazepine derivatives

1. A compound represented by any one of the following formulas:

or a pharmaceutically acceptable salt thereof, wherein:

one of L′, L″, and L′″ is represented by the following formula:

—Z 1 —P—Z 2 —R x -J  (A)

and the other two are the same or different, and are independently selected from —H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, —(CH 2 CH 2 O) n —R c , halogen, —NH(C═NH)NH 2 , —OR, —NR′R″, —NO 2 , —NR′COR″, —SR, —SOR′, —SO 2 R′, —SO 3 H, —OSO 3 H, —SO 2 NR′R″, cyano, an azido, —COR′, —OCOR′, and —OCONR′R″;

one of the Z 1 and Z 2 is —C(═O)—, and the other is —NR 5 —;

P is an amino acid residue or a peptide containing between 2 to 20 amino acid residues;

R x is an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms;

J is —COOH or —COE, wherein —COE represents a reactive ester and R c1 is —H or linear or branched alkyl having 1 to 4 carbon atoms optionally substituted with halogen, —OH or (C 1 -C 3 )alkoxy;

the double line between N and C represents a single bond or a double bond, provided that when it is a double bond X is absent and Y is —H, or a linear or branched alkyl having 1 to 4 carbon atoms, and when it is a single bond, X is —H or an amine protecting moiety;

Y is a leaving group selected from —OR, —OCOR′, —OCOOR′, —OCONR′R″, —NR′R″, —NR′COR″, —NR′NR′R″, an optionally substituted 5- or 6-membered nitrogen-containing monocyclic heterocycle —NR′(C═NH)NR′R″, an amino acid, or a peptide represented by —NRCOP′, —SR, —SOR′, halogen, cyano, azido, —OSO 3 H, —SO 3 H, —SO 2 H, H 2 S 2 O 5 , PO 3 SH 3 , PO 2 S 2 H 2 , POS 3 H 2 , PS 4 H 2 , (R i O) 2 PS(OR i ), R i S—, R i SO, R i SO 2 , R i SO 3 , HS 2 O 3 , HS 2 O 4 , P(═S)(OR k′ )(S)(OH), R k′ C(═O)NOH, and HOCH 2 SO 2 −1 or a mixture thereof, wherein R i is a linear or branched alkyl having 1 to 10 carbon atoms and is substituted with at least one substituent selected from —N(R j ) 2 , —CO 2 H, —SO 3 H, and —PO 3 H; R i can be further optionally substituted with a substituent for an alkyl described herein; R j is a linear or branched alkyl having 1 to 6 carbon atoms; R k′ is a linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms, aryl, heterocyclyl or heteroaryl;

P′ is an amino acid residue or a polypeptide containing between 2 to 20 amino acid residues,

R, for each occurrence, is independently selected from the group consisting of —H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, —(CH 2 CH 2 O) n —R c , an optionally substituted aryl having 6 to 18 carbon atoms, an optionally substituted 5- to 18-membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an optionally substituted 3- to 18-membered heterocyclic ring containing 1 to 6 heteroatoms independently selected from O, S, N and P;

R′ and R″ are each independently selected from —H, —OH, —OR, —NHR, —NR 2 , —COR, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, —(CH 2 CH 2 O) n —R c , and an optionally substituted 3- to 18-membered heterocyclic ring having 1 to 6 heteroatoms independently selected from O, S, N and P;

R c is —H or an optionally substituted linear or branched alkyl having 1 to 4 carbon atoms;

n is an integer from 1 to 24;

X′ is selected from —H, an amine-protecting group, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, —(CH 2 CH 2 O) n —R c , an optionally substituted aryl having 6 to 18 carbon atoms, an optionally substituted 5- to 18-membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an optionally substituted 3- to 18-membered heterocyclic ring containing 1 to 6 heteroatoms independently selected from O, S, N and P;

Y′ is selected from —H, an oxo group, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, an optionally substituted 6- to 18-membered aryl, an optionally substituted 5- to 18-membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur, an optionally substituted 3- to 18-membered heterocyclic ring having 1 to 6 heteroatoms;

R 1 , R 2 , R 3 , R 4 , R 1 ′, R 2 ′, R 3 ′ and R 4 ′ are each independently selected from the group consisting of —H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, —(CH 2 CH 2 O) n —R c , halogen, —NH(C═NH)NH 2 , —OR, —NR′R″, —NO 2 , —NCO, —NR′COR″, —SR, —SOR′, —SO 2 R′, —SO 3 − H, —OSO 3 H, —SO 2 NR′R″, cyano, an azido, —COR′, —OCOR′, and —OCONR′R″;

R 6 is —H, —R, —OR, —SR, —NR′R″, —NO 2 , or halogen;

G is —CH— or —N—;

A and A′ are the same or different, and are independently selected from —O—, C(═O)—, —CRR′O—, —CRR′—, —S—, —CRR'S—, —NR 5 and —CRR′N(R 5 )—; and

R 5 for each occurrence is independently —H or an optionally substituted linear or branched alkyl having 1 to 10 carbon atoms,

wherein the optional substituent described above is a linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon bon atoms, aryl, heteroaryl, heterocyclyl, halogen, —NH(C═NH)NH 2 , —OR 100 , NR 101 R 102 , —NO 2 , —NR 101 COR 102 , —SR 100 , —SOR 101 , —SO 2 R 101 , —SO 3 M, —OSO 3 M, —SO 2 NR 101 R 102 , cyano, an azido, —COR 101 , —OCOR 101 , —OCONR 101 R 102 or (—CH 2 CH 2 O) n R 101 , wherein M is H or a cation; R 101 , R 102 and R 103 are each independently selected from H, linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, (—CH 2 CH 2 O) n —R 104 , wherein n is an integer from 1 to 24, an aryl having from 6 to 10 carbon atoms, a heterocyclic ring having from 3 to 10 carbon atoms and a heteroaryl having 5 to 10 carbon atoms; and R 104 is H or a linear or branched alkyl having 1 to 4 carbon atoms, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl in the groups represented by R 100 , R 101 , R 102 , R 103 and R 104 are optionally substituted with one or more substituents independently selected from halogen, —OH, —CN, —NO 2 and unsubstituted linear or branched alkyl having 1 to 4 carbon atoms.

2. The compound of claim 1 , wherein L′ is represented by the following formula:

—NR 5 —P—C(═O)—(CR a R b ) m -J  (B1);

—NR 5 —P—C(═O)—Cy-(CR a R b ) m′ -J  (B2);

—C(═O)—P—NR 5 —(CR a R b ) m -J  (C1), or

—C(═O)—P—NR 5 —Cy-(CR a R b ) m′ -J  (C2),

wherein:

J is —COE;

R a and R b , for each occurrence, are each independently —H, (C 1 -C 3 )alkyl or a charged substituent or an ionizable group Q;

m is an integer from 1 to 6;

m′ is 0 or an integer from 1 to 6; and

Cy is a cyclic alkyl having 5 or 6 ring carbon atoms optionally substituted with halogen, —OH, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy, or halo(C 1 -C 3 )alkyl.

3. The compound of claim 1 , wherein L′ is represented by the following formula:

—NR 5 —P—C(═O)—(CR a R b ) m —S—Z s   (B3); or

—C(═O)—P—NR 5 —(CR a R b ) m —S—Z s   (C3),

wherein:

R a and R b , for each occurrence, are each independently —H, (C 1 -C 3 )alkyl or a charged substituent or an ionizable group Q;

m is an integer from 1 to 6;

Z s is —H, —SR d , —C(═O)R d1 or is selected from any one of the following formulas:

wherein:

q is an integer from 1 to 5;

n′ is an integer from 2 to 6;

U is —H or SO 3 M;

M is H + , Na + or K + ;

R d is a linear or branched alkyl having 1 to 6 carbon atoms or is selected from phenyl, nitrophenyl, dinitrophenyl, carboxynitrophenyl, pyridyl or nitropyridyl; and

R d1 is a linear or branched alkyl having 1 to 6 carbon atoms.

4. The compound of claim 2 , wherein P is a peptide containing 2 to 5 amino acid residues.

5. The compound of claim 4 , wherein P is selected from Gly-Gly-Gly, Ala-Val, Val-Ala, Val-Cit, Val-Lys, Phe-Lys, Lys-Lys, Ala-Lys, Phe-Cit, Leu-Cit, Lle-Cit, Phe-Ala, Phe-N 9 -tosyl-Arg, Phe-N 9 -nitro-Arg, Phe-Phe-Lys, D-Phe-Phe-Lys, Gly-Phe-Lys, Leu-Ala-Leu, Ile-Ala-Leu, Val-Ala-Val, Ala-Leu-Ala-Leu, β-Ala-Leu-Ala-Leu and Gly-Phe-Leu-Gly, Val-Arg, Arg-Val, Arg-Arg, Val-D-Cit, Val-D-Lys, Val-D-Arg, D-Val-Cit, D-Val-Lys, D-Val-Arg, D-Val-D-Cit, D-Val-D-Lys, D-Val-D-Arg, D-Arg-D-Arg, Ala-Ala, Ala-D-Ala, D-Ala-Ala, D-Ala-D-Ala, Ala-Met, and Met-Ala.

6. The compound of claim 5 , wherein:

the double line between N and C represents a single bond or double bond, provided that when it is a double bond X is absent and Y is —H, and when it is a single bond, X is —H, Y is —OH or —SO 3 M;

R 1 , R 2 , R 3 , R 4 , R 1 ′, R 2 ′, R 3 ′ and R 4 ′ are all —H;

R 6 is —OMe;

X′ and Y′ are both —H;

A and A′ are —O—; and

M is H, Na + or K + .

7. The compound of claim 1 , wherein the compound is selected from any one of the following formulas:

or a pharmaceutically acceptable salt thereof, wherein:

R 100 is —OH, —OMe or

Y is —H, —OH or —SO 3 M;

M is H + , Na + or K + ;

Z s is —H, —SR d , —C(═O)R d1 or is selected from any one of the following formulas:

wherein:

q is an integer from 1 to 5;

n′ is an integer from 2 to 6;

U is —H or SO 3 M; and

R d is a linear or branched alkyl having 1 to 6 carbon atoms or is selected from phenyl, nitrophenyl, dinitrophenyl, carboxynitrophenyl, pyridyl and nitropyridyl; and

R d1 is a linear or branched alkyl having 1 to 6 carbon atoms.

8. A conjugate comprising a compound and a cell-binding agent (CBA), wherein the compound is covalently linked to the CBA, and wherein said compound is represented by any one of the following formulas:

or a pharmaceutically acceptable salt thereof, wherein:

one of L′, L″, and L′″ is represented by the following formula:

—Z 1 —P—Z 2 —R x -J′  (A′)

and the other two are the same or different, and are independently selected from —H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, —(CH 2 CH 2 O) n —R c , halogen, NH(C═NH)NH 2 , —OR, —NR′R″, —NO 2 , —NR′COR″, —SR, a sulfoxide represented by —SOR′, a sulfone represented by —SO 2 R′, a sulfonate —SO 3 M, a sulfate —OSO 3 M, a sulfonamide represented by —SO 2 NR′R″, cyano, an azido, —COR′, —OCOR′, and —OCONR′R″;

one of the Z 1 and Z 2 is —C(═O)—, and the other is —NR 5 —;

P is an amino acid residue or a peptide containing between 2 to 20 amino acid residues;

R x is an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms;

J′ is —C(═O)—;

R c1 is —H or linear or branched alkyl having 1 to 4 carbon atoms optionally substituted with halogen, —OH or (C 1 -C 3 )alkoxy;

the double line between N and C represents a single bond or a double bond, provided that when it is a double bond X is absent and Y is —H, or a linear or branched alkyl having 1 to 4 carbon atoms, and when it is a single bond, X is —H or an amine protecting moiety;

Y is a leaving group selected from —OR, —OCOR′, —OCOOR′, —OCONR′R″, —NR′R″, —NR′COR″, —NR′NR′R″, an optionally substituted 5- or 6-membered nitrogen-containing monocyclic heterocycle, —NR′(C═NH)NR′R″, an amino acid residue, or a peptide represented by —NRCOP′, —SR, —SOR′, halogen, cyano, azido, —OSO 3 H, —SO 3 H, —SO 2 H, H 2 S 2 O 5 , PO 3 SH 3 , PO 2 S 2 H 2 , POS 3 H 2 , PS 4 H 2 , (R i O) 2 PS(OR i ), R i S—, R i SO, R i SO 2 , R i SO 3 , HS 2 O 3 , HS 2 O 4 , (P(═S)(OR k′ )(S)(OH), R k′ C(═O)NOH, and HOCH 2 SO 2 − or a mixture thereof, wherein R i is a linear or branched alkyl having 1 to 10 carbon atoms and is substituted with at least one substituent selected from —N(R j ) 2 , —CO 2 H, —SO 3 H, and —PO 3 H; R i can be further optionally substituted with a substituent for an alkyl described herein; R j is a linear or branched alkyl having 1 to 6 carbon atoms; R k′ is a linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms, aryl, heterocyclyl or heteroaryl;

P′ is an amino acid residue or a polypeptide containing 2 to 20 amino acid residues;

R, for each occurrence, is independently selected from the group consisting of —H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, —(CH 2 CH 2 O) n —R c , an optionally substituted aryl having 6 to 18 carbon atoms, an optionally substituted 5- to 18-membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an optionally substituted 3- to 18-membered heterocyclic ring containing 1 to 6 heteroatoms independently selected from O, S, N and P;

R′ and R″ are each independently selected from —H, —OH, —OR, —NHR, —NR 2 , —COR, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, —(CH 2 CH 2 O) n —R c , and an optionally substituted 3- to 18-membered heterocyclic ring having 1 to 6 heteroatoms independently selected from O, S, N and P;

R c is —H or an optionally substituted linear or branched alkyl having 1 to 4 carbon atoms;

n is an integer from 1 to 24;

X′ is selected from —H, an amine-protecting group, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a —(CH 2 CH 2 O) n —R c , an optionally substituted aryl having 6 to 18 carbon atoms, an optionally substituted 5- to 18-membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an optionally substituted 3- to 18-membered heterocyclic ring containing 1 to 6 heteroatoms independently selected from O, S, N and P;

Y′ is selected from —H, an oxo group, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, an optionally substituted 6- to 18-membered aryl, an optionally substituted 5- to 18-membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur, an optionally substituted 3- to 18-membered heterocyclic ring having 1 to 6 heteroatoms;

R 1 , R 2 , R 3 , R 4 , R 1 ′ , R 2 ′ , R 3 ′ and R 4 ′ are each independently selected from the group consisting of —H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, —(CH 2 CH 2 O) n —R c , halogen, —NH(C═NH)NH 2 , —OR, —NR′R″, —NO 2 , —NCO, —NR′COR″, —SR, —SOR′, —SO 2 R′, —SO 3 H, —OSO 3 H, —SO 2 NR′R″, cyano, an azido, —COR′, —OCOR′, and —OCONR′R″;

R 6 is —H, —R, —OR, —SR, —NR′R″, —NO 2 , or halogen;

G is —CH— or —N—;

A and A′ are the same or different, and are independently selected from —O—, —C(═O)—, —CRR′O—, —CRR′—, —S—, —CRR′S—, —NR 5 and —CRR′N(R 5 )—;

R 5 for each occurrence is independently —H or an optionally substituted linear or branched alkyl having 1 to 10 carbon atoms,

wherein the optional substituent described above is a linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, aryl, heteroaryl, heterocyclyl, halogen, —NH(C═NH)NH 2 , —OR 100 , NR 101 R 102 , —NO 2 , —NR 101 COR 102 , —SR 100 , —SOR 101 , —SO 2 R 101 , —SO 3 M, —OSO 3 M, —SO 2 NR 101 R 102 , cyano, an azido, —COR 101 , —OCOR 101 , —OCONR 101 R 102 or a polyethylene glycol unit (—CH 2 CH 2 O) n R 101 , wherein M is H or a cation; R 101 , R 102 and R 103 are each independently selected from H, linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit (—CH 2 CH 2 O) n —R 104 , wherein n is an integer from 1 to 24, an aryl having from 6 to 10 carbon atoms, a heterocyclic ring having from 3 to 10 carbon atoms and a heteroaryl having 5 to 10 carbon atoms; and R 104 is H or a linear or branched alkyl having 1 to 4 carbon atoms, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl in the groups represented by R 100 , R 101 , R 102 , R 103 and R 104 are optionally substituted with one or more substituents independently selected from halogen, —OH, —CN, —NO 2 and unsubstituted linear or branched alkyl having 1 to 4 carbon atoms.

9. The conjugate of claim 8 , wherein L′ is represented by the following formula:

—NR 5 —P—C(═O)—(CR a R b ) m -J′  (B1′);

—NR 5 —P—C(═O)—Cy-(CR a R b ) m′ -J′  (B2′);

—C(═O)—P—NR 5 —(CR a R b ) m -J′  (C1′), or

—C(═O)—P—NR 5 —Cy-(CR a R b ) m′ -J′  (C2′)

wherein:

J′ is —C(═O)—;

R a and R b , for each occurrence, are each independently —H, (C 1 -C 3 )alkyl or a charged substituent or an ionizable group Q;

m is an integer from 1 to 6;

m′ is 0 or an integer from 1 to 6; and

Cy is a cyclic alkyl having 5 or 6 ring carbon atoms optionally substituted with halogen, —OH, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy, or halo(C 1 -C 3 )alkyl.

10. The conjugate of claim 8 , wherein L′ is represented by the following formula:

—NR 5 —P—C(═O)—(CR a R b ) m —S—Z s1   (B3′); or

—C(═O)—P—NR 5 —(CR a R b ) m —S—Z s1   (C3′),

wherein:

R a and R b , for each occurrence, are each independently —H, (C 1 -C 3 )alkyl, or a charged substituent or an ionizable group Q;

m is an integer from 1 to 6;

Z s1 is selected from any one of the following formulas:

wherein:

q is an integer from 1 to 5;

n′ is an integer from 2 to 6;

U is —H or SO 3 M; and

M is H + , Na + or K + .

11. The conjugate of claim 9 , wherein P is a peptide containing 2 to 5 amino acid residues.

12. The conjugate of claim 9 , wherein P is selected from Gly-Gly-Gly, Ala-Val, Val-Ala, Val-Cit, Val-Lys, Phe-Lys, Lys-Lys, Ala-Lys, Phe-Cit, Leu-Cit, Lle-Cit, Phe-Ala, Phe-N 9 -tosyl-Arg, Phe-N 9 -nitro-Arg, Phe-Phe-Lys, D-Phe-Phe-Lys, Gly-Phe-Lys, Leu-Ala-Leu, Ile-Ala-Leu, Val-Ala-Val, Ala-Leu-Ala-Leu, β-Ala-Leu-Ala-Leu, Gly-Phe-Leu-Gly, Val-Arg, Arg-Val, Arg-Arg, Val-D-Cit, Val-D-Lys, Val-D-Arg, D-Val-Cit, D-Val-Lys, D-Val-Arg, D-Val-D-Cit, D-Val-D-Lys, D-Val-D-Arg, D-Arg-D-Arg, Ala-Ala, Ala-D-Ala, D-Ala-Ala, D-Ala-D-Ala, Ala-Met, and Met-Ala.

13. The conjugate of claim 12 , wherein:

the double line between N and C represents a single bond or double bond, provided that when it is a double bond X is absent and Y is —H, and when it is a single bond, X is —H, Y is —OH or —SO 3 M;

R 1 , R 2 , R 3 , R 4 , R 1 ′, R 2 ′, R 3 ′ and R 4 ′ are all —H;

R 6 is —OMe;

X′ and Y′ are both —H;

A and A′ are —O—; and

M is H, Na + or K + .

14. The conjugate of claim 8 , wherein the compound is selected from any one of the following formulas:

or a pharmaceutically acceptable salt thereof, wherein:

r is an integer from 1 to 10;

Y is —H, —OH or —SO 3 M; and

M is H + , Na + or K + .

15. The conjugate of claim 8 , wherein the cell-binding agent (CBA) binds to target cells selected from tumor cells, virus infected cells, microorganism infected cells, parasite infected cells, autoimmune cells, activated cells, myeloid cells, activated T-cells, B cells, or melanocytes; cells expressing the CD4, CD6, CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD40, CD44, CD56, EpCAM, CanAg, CALLA, or Her-2 antigens; Her-3 antigens; or cells expressing insulin growth factor receptor, epidermal growth factor receptor, and folate receptor.

16. The conjugate of claim 8 , wherein the cell-binding agent is an antibody, a single chain antibody, an antibody fragment that specifically binds to the target cell, a monoclonal antibody, a single chain monoclonal antibody, or a monoclonal antibody fragment that specifically binds to a target cell, a chimeric antibody, a chimeric antibody fragment that specifically binds to the target cell, a domain antibody, a domain antibody fragment that specifically binds to the target cell, a lymphokine, a hormone, a vitamin, a growth factor, a colony stimulating factor, or a nutrient-transport molecule.

17. A pharmaceutical composition comprising the conjugate of claim 8 and a pharmaceutically acceptable carrier.

18. A method of treating a cancer selected from ovarian cancer, cervical cancer, lung cancer, breast cancer, squamous cell carcinoma of the head and neck, endometrial cancer, lymphoma, and leukemia in a mammal, comprising administering to said mammal a therapeutically effective amount of a conjugate of claim 8 , and optionally, a chemotherapeutic agent.

19. The compound of claim 7 , wherein the compound is represented by the following formula:

or a pharmaceutically acceptable salt thereof.

20. The conjugate of claim 14 , wherein the conjugate is represented by the following formula:

or a pharmaceutically acceptable salt thereof.

21. The conjugate of claim 14 , wherein the cell-binding agent is an antibody or an antibody fragment thereof.

22. The conjugate of claim 21 , wherein the cell-binding agent is an anti-folate receptor antibody or an antibody fragment thereof, an anti-EGFR antibody or an antibody fragment thereof, an anti-CD33 antibody or an antibody fragment thereof, an anti-CD19 antibody or an antibody fragment thereof, an anti-Muc1 antibody or an antibody fragment thereof, or an anti-CD37 antibody or an antibody fragment thereof.

23. The conjugate of claim 20 , wherein the cell-binding agent is an antibody or an antibody fragment thereof.

24. The conjugate of claim 23 , wherein the cell-binding agent is an anti-folate receptor antibody or an antibody fragment thereof, an anti-EGFR antibody or an antibody fragment thereof, an anti-CD33 antibody or an antibody fragment thereof, an anti-CD19 antibody or an antibody fragment thereof, an anti-Muc1 antibody or an antibody fragment thereof, or an anti-CD37 antibody or an antibody fragment thereof.

25. The method of claim 18 , wherein the conjugate is represented by the following formula:

or a pharmaceutically acceptable salt thereof, wherein r is an integer from 1 to 10; and M is H + , Na + or K + .

26. The method of claim 25 , wherein the cell-binding agent is an antibody or an antibody fragment thereof.

27. The method of claim 18 , wherein the cancer is acute myeloid leukemia (AML) or non small-cell lung cancer.

28. The method of claim 26 , wherein the cancer is acute myeloid leukemia (AML) or non small-cell lung cancer.